<DOC>
	<DOCNO>NCT00765856</DOCNO>
	<brief_summary>Patients convert current opioid Oxymorphone ER undergo titration . During Titration Period , subject receive daily oxymorphone Extended Release tablet ( ) every 12 hour . Dosing adjustment base review subject 's pain score . Oxymorphone IR 5 mg provide used supplemental `` breakthrough '' pain medication ( need ) . Titration Period end fix dose study medication tolerate subject achieves adequate analgesia . Subjects proceed open-label 3-month maintenance period fix dose study medication establish Titration Period .</brief_summary>
	<brief_title>Open-Label Safety Tolerability Oxymorphone IR ER Opioid Tolerant Pediatric Subjects</brief_title>
	<detailed_description>An Open-Label Safety Tolerability Study Immediate-Release Extended-Release Oxymorphone Opioid-Tolerant Pediatric Subjects With Chronic Pain .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>Have chronic cancer noncancer pain , currently require treatment pain strong opioid least 5 day ( 3 5 day dose great equal 45 mg/daily ( qd ) oral morphine equivalent ) Weigh least 50 kg Expected continue require strong opioid pain relief least 4 week 4 month . Have life expectancy &lt; 4 week Plan undergo surgical procedure within 3 day study entry Titration Period Have dysphagia difficulty swallow whole tablet Have previous exposure oxymorphone Have ileostomy</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Opioid tolerant</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Male 6-17 year age</keyword>
	<keyword>Female 6-17 year age</keyword>
	<keyword>Pain</keyword>
	<keyword>Non malignant</keyword>
	<keyword>Malignant</keyword>
</DOC>